Halozyme Therapeutics, Inc. (HALO) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à San Diego, CA, United States. Le PDG actuel est Helen I. Torley.
HALO a date d'introduction en bourse 2004-03-16, 350 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $7.97B.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. The company's core proprietary technology, ENHANZE, is based on a recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Halozyme develops and commercializes multiple products across oncology, immunology, and rare disease areas, including Hylenex, RITUXAN HYCELA, HYQVIA, and collaborates with leading pharmaceutical companies such as Roche, Pfizer, AbbVie, and Bristol-Myers Squibb on various therapeutic programs targeting cancer, autoimmune diseases, and infectious diseases. Founded in 1998, the company leverages its advanced drug delivery platform to enhance the efficacy and patient convenience of treatments across multiple therapeutic areas.
